RNACCartesian Therapeutics, Inc.

$216M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$903,000+5211.8% YoY

Gross Profit

$903,000100.0% margin

Operating Income

-$14M-1605.6% margin

Net Income

-$15M-1622.5% margin

EPS (Diluted)

$-19.58

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$44M

Total Liabilities

$50M

Stockholders' Equity

-$5M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$903,000	$17,000	+5211.8%
Gross Profit	$903,000	$17,000	+5211.8%
Operating Income	-$14M	-$19M	+24.8%
Net Income	-$15M	-$20M	+25.0%

RNAC Q4 2018 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena